Antiviral Drugs - Kazakhstan

Kazakhstan

The revenue in Kazakhstan's Antiviral Drugs market is estimated to reach US$18.34m by 2024.
It is projected to exhibit an annual growth rate (CAGR 2024-2029) of 2.12%, leading to a market volume of US$20.37m by 2029.
When compared globally, United States is expected to generate the highest revenue of US$30,640.00m in 2024.
"Kazakhstan's growing pharmaceutical industry is witnessing an increased demand for locally-produced antiviral drugs amidst the ongoing pandemic."

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in Kazakhstan has been steadily growing in recent years.

Customer preferences: The customers in Kazakhstan are becoming increasingly aware of the importance of preventative healthcare and are more willing to invest in antiviral drugs to protect themselves from potential illnesses. Additionally, the COVID-19 pandemic has led to a surge in demand for antiviral drugs, as people are seeking ways to boost their immune systems and protect themselves from the virus.

Trends in the market: One of the key trends in the Antiviral Drugs market in Kazakhstan is the increasing availability of generic drugs. This has led to a decrease in the prices of antiviral drugs, making them more accessible to a wider range of customers. Additionally, there has been a shift towards more natural and herbal remedies, as people become more interested in traditional medicine and alternative treatments.

Local special circumstances: Kazakhstan is a rapidly developing country with a growing middle class. As a result, the demand for healthcare products, including antiviral drugs, is increasing. However, there are still challenges to overcome, such as a lack of infrastructure and resources in certain regions of the country. Additionally, there is a need for greater education and awareness about the benefits of antiviral drugs, particularly in rural areas.

Underlying macroeconomic factors: The Antiviral Drugs market in Kazakhstan is influenced by a range of macroeconomic factors, including the country's GDP growth, inflation rates, and government policies. The government has implemented a range of policies aimed at improving healthcare access and affordability, which has had a positive impact on the Antiviral Drugs market. Additionally, the country's growing middle class and increasing disposable income levels are driving demand for healthcare products, including antiviral drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.